- Home
- ATCX vs VYNE Comparison
ATCX vs VYNE Comparison
Compare ATCX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Brazil | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 22.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATCX | VYNE |
|---|---|---|
| Price | $3.78 | $0.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | 22.9K | ★ 149.3K |
| Earning Date | 03-16-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $827,667.00 | N/A |
| Revenue Next Year | $166.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.77 | $0.29 |
| 52 Week High | $14.01 | $1.96 |
Technical Indicators
Market Signals| Indicator | ATCX | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 26.04 | 46.32 |
| Support Level | N/A | $0.56 |
| Resistance Level | $5.62 | $0.69 |
| Average True Range (ATR) | 0.35 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 3.45 | 50.15 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.